Clavutil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-β-lactamase–producing strains only). Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (β-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including β-lactamase–producing strains) or Streptococcus pyogenes. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae. Uncomplicated Gonorrhea, (urethral and endocervical) caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae. Early Lyme disease (erythema migrans) caused by Borrelia burgdorferi.